Abstract
Purpose of Review: The pathophysiology of preeclampsia is complex and not entirely understood. A key feature in preeclampsia development is an immunological imbalance that shifts the maternal immune response from one of tolerance towards one promoting chronic inflammation and endothelial dysfunction. As a key regulator of immunity, IL-10 not only has immunomodulatory activity, but also directly benefits vasculature and promotes successful cellular interactions at the maternal-fetal interface. Here we focus on the mechanisms by which the dysregulation of IL-10 may contribute to the pathophysiology of preeclampsia. Recent Findings: Dysregulation of IL-10 has been demonstrated in various animal models of preeclampsia. Decreased IL-10 production in both placenta and peripheral blood mononuclear cells has been reported in human studies, but with inconsistent results. Summary: The significance of IL-10 in preeclampsia has shifted from a key biomarker to one with therapeutic potential. As such, a better understanding of the role of this cytokine in the pathophysiology of preeclampsia is of paramount importance.
| Original language | English (US) |
|---|---|
| Article number | 36 |
| Journal | Current Hypertension Reports |
| Volume | 20 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 1 2018 |
Keywords
- Cytokines
- Hypertension
- Inflammation
- Interleukin 10
- Preeclampsia
- Regulatory T cells
- Vascular activity
ASJC Scopus subject areas
- Internal Medicine